31May

Eribulin and pembrolizumab disappointed with its efficacy results in Uterine leiomyosarcoma (LMS)

Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.


Abstract No : 11559

Abstract Type : Poster session

Indication : Uterine Leiomyosarcoma

Intervention : eribulin + pembrolizumab

Company : Eisai Pharmaceutical

Technology : Small molecule/monoclonal antibody


Results:

Nineteen pts with LMS were enrolled from May 2019 to Sept 2019. The median age was 62 (range 48-80). Eleven (58%) patients had uterine LMS. The median # of prior therapies was 4 (range 1-7). The median follow-up was 19.7 weeks. The PFS at 12 weeks was 42.1% (90% CI: 27.0%-65.5%), with median PFS of 11.1 weeks. Median OS was not reached during the follow-up period. There was 1 partial response, and 5 confirmed stable disease for ORR of 5.3% and CBR of 26.3%, after 12 weeks. The rate of grade 3 or higher toxicity was 68% overall, most commonly neutropenia, anemia, weight loss, diarrhea, elevations of lipase, and alkaline phosphatase. These side effects were reversible. The most common adverse events were fatigue, neutropenia, anorexia, AST increase, and nausea.


Conclusion:

Eribulin and pembrolizumab in LMS did not meet the predefined endpoint for efficacy. The LPS and “other STS subtype” cohorts of this trial are actively enrolling


Commentary:

Eribulin and pembrolizumab in LMS did not meet the predefined endpoint for efficacy.


Refer to Uterine Leiomyosarcoma Market report for detailed Insights.